--- title: "Context Therapeutics closes Delaware suit over three-year director terms" url: "https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-05" section: "Legal" tickers: "NASDAQ:CNTX" source: "https://www.sec.gov/Archives/edgar/data/1842952/000162828026053347/cntx-20260630.htm" summary: "The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third par" --- By the aibio.space news desk. Sources - [Context Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026053347/cntx-20260630.htm) - [Context Therapeutics 10-K for the year ended December 31, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/cntx-20251231.htm) - [Context Therapeutics 8-K dated February 24, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026012813/cntx-20260224.htm) - [Context Therapeutics 8-K dated March 11, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026017691/cntx-20260311.htm) - [Context Therapeutics 8-K dated April 30, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026029323/cntx-20260430.htm) - [Context Therapeutics 8-K dated June 24, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm) [CNTX](https://aibio.space/companies/context-therapeutics/) 2026-08-05 # Context Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid Tickers [CNTX](https://aibio.space/companies/context-therapeutics/) The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000. ## Key facts - **Company**: Context Therapeutics Inc. (NASDAQ: CNTX) - **News type**: Legal - **Primary source**: [Context Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1842952/000162828026053347/cntx-20260630.htm) *Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.* Context Therapeutics Inc. (Nasdaq: [CNTX](https://aibio.space/companies/context-therapeutics/)) said in its [10-Q filed August 5, 2026](https://www.sec.gov/Archives/edgar/data/1842952/000162828026053347/cntx-20260630.htm) that a Delaware class action challenging its director terms has been closed. The Vladimir Gusinsky Revocable Trust filed a stockholder class action complaint on February 4, 2026 in the Court of Chancery of the State of Delaware against the company and its directors. The defendants are Context and its directors. The 10-Q does not name the directors or give a case number. Context's board, according to its [10-K signed March 23, 2026](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/cntx-20251231.htm), was Martin Lehr, Andy Pasternak, Philip Kantoff, Karen Smith, Jennifer Evans Stacey, Luke Walker and Linda West. No filing names the individual directors sued. The claims described here are allegations. ## The case The complaint asserted two points. First, it said Article V, Section 2 of Context's Amended and Restated Certificate of Incorporation, as amended, gives directors a full three-year term, in violation of Section 211(b) of the General Corporation Law of the State of Delaware. Second, it said Article VI, Section 1 allows directors to be removed only for cause, in violation of Section 141(k). The 10-Q describes no claim for damages. ## Defendants Context Therapeutics Inc. and its directors. The 8-Ks describe the action as brought against the company and its directors. According to the 10-K, Lehr is chief executive officer and a director, and Pasternak is chairman of the board. Kantoff, Smith, Stacey, Walker and West are listed as directors. The company's chief financial officer, Jennifer Minai-Azary, also signed the 10-K, but no filing says she is a defendant. ## Where it stands On February 24, 2026 the parties filed a stipulation and proposed consent judgment. An [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026012813/cntx-20260224.htm) said the parties asked the court to declare both provisions invalid and unenforceable. The stipulation also provided for dismissal with prejudice and for the 2026 annual meeting to be held on June 24, 2026. The court approved the stipulated judgment on March 11, 2026. Both provisions were determined to be invalid and unenforceable. Context filed a Certificate of Correction with the Delaware Secretary of State the same day, and the court dismissed the action with prejudice as to the plaintiff. It kept jurisdiction over any mootness fee application, according to an [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026017691/cntx-20260311.htm). On April 30, 2026, Context signed a letter agreement under which a third party service provider would pay the fee on its behalf. The court entered a stipulated order closing the case, which requires $850,000 in fees and expenses to plaintiff's counsel. The court was not asked to review, and did not pass judgment on, whether the fee was owed or its amount. The provider paid it in full on May 1, 2026, per an [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026029323/cntx-20260430.htm). That 8-K said the case would be closed once the court was told a quorum was reached at the June 24, 2026 annual meeting. The 10-Q rounds the figure to $0.9 million and says the action has since been closed. ## Why it matters to shareholders The consent judgment changes how Context's board is elected. The terms of the current directors were to end at the 2026 annual meeting, and directors can now be removed with or without cause by holders of a majority of the shares entitled to vote at a director election. At the June 24, 2026 meeting, stockholders [elected all seven nominees](https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm) to serve until the 2027 annual meeting. Shares present were 72,830,990, about 79.27% of those outstanding on the record date. On cost, the company did not itself pay the $850,000. The filings do not name the provider or say whether Context must reimburse it. The 10-Q reports no appeal or related claim. Context says that, apart from this action, it is not presently a party to any material legal proceedings. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story CNTX Context Therapeutics Inc. NASDAQ ยท United States Open the starter desk ## More in Legal Legal ### [Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) Oct 29, 2026 Legal ### [Viking and Ligand dispute VK2809 license termination in San Diego court](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/) Oct 29, 2026 Legal ### [Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit](https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/) Oct 29, 2026 --- Source page: https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Context Therapeutics closes Delaware suit over three-year director terms", 2026-08-05, https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/